ArticleEuropean journal of nuclear medicine and molecular imaging2026
PET-based risk stratification for adverse events under [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeActinium-225 prostate-specific membrane antigen radioligand therapy ([225Ac]Ac-PSMA RLT) is a promising salvage option for metastatic castration-resistant prostate cancer (mCRPC). This study aimed to identify predictive parameters for renal and hematological adverse events.
methodsTwenty-six patients undergoing [225Ac]Ac-PSMA-I&T RLT (mean 3 ± 1 cycles) were retrospectively included. All patients received pretherapeutic Fluor-18 ([18F]F)-PSMA-1007 positron emission tomography/computed tomography (PET/CT) to quantify renal standardized uptake values (SUV) through manual segmentation of both kidneys. Total and osseous PSMA-tumor volume (TV) were also calculated. Additionally, Technetium-99m ([99mTc]Tc)-mercaptoacetyltriglycine (MAG3) renal scintigraphy was performed to assess tubular extraction rates (TER). Standard laboratory values were evaluated at baseline, at and between treatment cycles, including estimated glomerular filtration rate (eGFR) and hemoglobin (Hb). Renal events were defined as an eGFR decline ≥ 20% (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group recommendations), while anemia was classified according to common terminology criteria of adverse events (CTCAE) version 5.
resultsBoth eGFR (P = 0.0018) and Hb (P = 0.0002) declined during therapy. Eight patients (31%) experienced renal events, and ten subjects (38%) developed grade 3 anemia. Renal SUV on [18F]F-PSMA-1007 PET/CT correlated with both eGFR and TER (r ≥ 0.413, P ≤ 0.036), suggesting that PET-based renal quantification may reflect renal function. SUV emerged as the strongest predictor of renal events (Odds Ratio [OR] = 0.095, P = 0.011) outperforming TER (P = 0.165) and baseline eGFR (P = 0.245). Based on Kaplan Meier analysis, low SUV was also associated with shorter renal event-free survival (P = 0.001). Baseline Hb (P = 0.002) was the strongest predictor of grade 3 anemia, while additional markers (platelets, white blood cell count, alkaline phosphatase, osseous PSMA-TV and lactate dehydrogenase; each P ≤ 0.037) also contributed. In line, baseline Hb emerged as the strongest predictor of anemia-free survival (P = 0.0007; osseous TV, P = 0.024).
conclusionPET-derived renal SUV and osseous tumor volume are promising predictive markers for renal and hematological adverse events during [225Ac]Ac-PSMA-I&T RLT. These findings may support pretherapeutic risk stratification in this vulnerable patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.